59 related articles for article (PubMed ID: 23805980)
1. MDR1 mRNA expression and MDR1 gene variants as predictors of response to chemotherapy in patients with acute myeloid leukaemia: a meta-analysis.
Doxani C; Voulgarelis M; Zintzaras E
Biomarkers; 2013 Aug; 18(5):425-35. PubMed ID: 23805980
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
van der Holt B; Van den Heuvel-Eibrink MM; Van Schaik RH; van der Heiden IP; Wiemer EA; Vossebeld PJ; Löwenberg B; Sonneveld P
Clin Pharmacol Ther; 2006 Nov; 80(5):427-39. PubMed ID: 17112800
[TBL] [Abstract][Full Text] [Related]
3. C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia.
Hur EH; Lee JH; Lee MJ; Choi SJ; Lee JH; Kang MJ; Seol M; Jang YE; Lee HJ; Kang IS; Shim SK; Ryu SG; Kang YA; Lee YS; Park CJ; Chi HS; Lee KH
Leuk Res; 2008 Oct; 32(10):1601-4. PubMed ID: 18272218
[TBL] [Abstract][Full Text] [Related]
4. Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods.
Zhou DC; Marie JP; Suberville AM; Zittoun R
Leukemia; 1992 Sep; 6(9):879-85. PubMed ID: 1355575
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between MDR1 genetic polymorphism and prognosis in acute myeloid leukemia].
Wang D; Ke XY; Wang J; Xu F; Hu YF
Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1384-8. PubMed ID: 17785057
[TBL] [Abstract][Full Text] [Related]
6. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia.
Efferth T; Sauerbrey A; Steinbach D; Gebhart E; Drexler HG; Miyachi H; Chitambar CR; Becker CM; Zintl F; Humeny A
Int J Oncol; 2003 Aug; 23(2):509-17. PubMed ID: 12851703
[TBL] [Abstract][Full Text] [Related]
7. Genomic variation at the MDR1 promoter and P-glycoprotein expression and activity in AML patients.
Lourenço JJ; Maia RC; Scheiner MA; Vasconcelos FC; Moreira MA
Leuk Res; 2008 Jun; 32(6):976-9. PubMed ID: 18001833
[TBL] [Abstract][Full Text] [Related]
8. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
9. MDR1 gene expression in acute myeloid leukemia: clinical correlation.
Lin SF; Huang SM; Chen TP; Chang CS; Liu TC; Wang SJ; Liu HW
J Formos Med Assoc; 1995 Mar; 94(3):111-6. PubMed ID: 7613241
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance in haematological malignancies.
Sonneveld P
J Intern Med; 2000 May; 247(5):521-34. PubMed ID: 10809991
[TBL] [Abstract][Full Text] [Related]
11. Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia.
Heuser M; Wingen LU; Steinemann D; Cario G; von Neuhoff N; Tauscher M; Bullinger L; Krauter J; Heil G; Döhner H; Schlegelberger B; Ganser A
Haematologica; 2005 Nov; 90(11):1484-92. PubMed ID: 16266895
[TBL] [Abstract][Full Text] [Related]
12. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients.
Illmer T; Schuler US; Thiede C; Schwarz UI; Kim RB; Gotthard S; Freund D; Schäkel U; Ehninger G; Schaich M
Cancer Res; 2002 Sep; 62(17):4955-62. PubMed ID: 12208746
[TBL] [Abstract][Full Text] [Related]
13. Role of the highly structured 5'-end region of MDR1 mRNA in P-glycoprotein expression.
Randle RA; Raguz S; Higgins CF; Yagüe E
Biochem J; 2007 Sep; 406(3):445-55. PubMed ID: 17573715
[TBL] [Abstract][Full Text] [Related]
14. Relationship between MDR1 gene and surface markers in acute myeloid leukemia.
Zöchbauer S; Schwarzinger I; Strobl H; Lechner K; Pirker R
Anticancer Res; 1997; 17(1B):749-52. PubMed ID: 9066614
[TBL] [Abstract][Full Text] [Related]
15. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK).
Lohri A; van Hille B; Bacchi M; Fopp M; Joncourt F; Reuter J; Cerny T; Fey MF; Herrmann R
Eur J Haematol; 1997 Oct; 59(4):206-15. PubMed ID: 9338618
[TBL] [Abstract][Full Text] [Related]
16. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients.
Taheri M; Mahjoubi F; Omranipour R
Genet Mol Res; 2010 Jan; 9(1):34-40. PubMed ID: 20082268
[TBL] [Abstract][Full Text] [Related]
17. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
[TBL] [Abstract][Full Text] [Related]
18. Association between MDR1 C3435T polymorphism and risk of breast cancer.
Wang Z; Wang T; Bian J
Gene; 2013 Dec; 532(1):94-9. PubMed ID: 24070710
[TBL] [Abstract][Full Text] [Related]
19. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells.
Tsang WP; Kwok TT
Oncogene; 2007 Jul; 26(33):4877-81. PubMed ID: 17297456
[TBL] [Abstract][Full Text] [Related]
20. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.
Rao AV; Valk PJ; Metzeler KH; Acharya CR; Tuchman SA; Stevenson MM; Rizzieri DA; Delwel R; Buske C; Bohlander SK; Potti A; Löwenberg B
J Clin Oncol; 2009 Nov; 27(33):5580-6. PubMed ID: 19858393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
